Posts in tag

BioSig Technologies


Westport, CT, May 28, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Natasha Drapeau, Executive Vice President of BioSig Technologies, Inc. would …

Westport, CT, April 08, 2021 (GLOBE NEWSWIRE) — Leading industry publication highlights the rising importance of intracardiac signals in complex cardiac ablations that treat irregular heart rhythm disorders High-quality intracardiac signals are deemed essential to determine ablation endpoints PURE EP™’s signals are described as ‘indispensable’ by the physician user BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” …

Westport, CT, June 04, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that two scientific sessions highlighting PURE EP(tm) System have been …

Westport, CT, Sept. 05, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that its subsidiary, NeuroClear Technologies, Inc., raised $3.7 million in an initial seed round. Founded in November 2018, NeuroClear …